In this episode, I discuss corneal disease and treatments with David Eveleth, PhD, the founder, president and CEO of Trefoil Therapeutics.

Brought to you by Alcon

·       Welcome to another exciting episode of Eye Care insider :14

·       Intro David Eveleth, PhD :47

·       Eveleth’s background 1:05

·       What’s the treatment landscape now for corneal diseases and where are we falling short for patients? 2:59

·       The origins of Trefoil Therapeutics 7:27

·       FGF-1: Is it just important in the endothelium or is it also important in the epithelium? 11:47

·       What is your current lead investigational candidate? 14:01

·       When do you expect another read out of clinical data? 21:47

·       An adjunctive therapy with cataract surgery 18:27

·       What is the timeline of administration to patients? 19:24

·       When do you expect a readout of clinical data? 20:49

·       Is it possible to use this also for the epithelium? 21:39

·       What are the most important challenges facing the ophthalmic industry? What is the most important factor to look for? 24:07

·       For more information about David Eveleth, PhD, and Trefoil Therapeutics, visit www.trefoiltherapeutics.com 25:53

·       Corneal disease can be fixed and better vision is possible 26:44

·       Thanks for listening 27:04

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. You can find follow Trefoil Therapeutics on Twitter @TrefoilThera.

David Eveleth, PhD, is the president and CEO of Trefoil Therapeutics.

Disclosures: Eveleth is the founder, CEO and shareholder of Trefoil Therapeutics. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI.

In this episode, I chat with Nancy Lurker, CEO and board director, about EyePoint Pharmaceuticals and their latest treatments and trials.

Brought to you by Alcon

·       Welcome to another exciting episode of Eye Care insider :13

·       Intro Nancy Lurker :22

·       Lurker’s background :58

·       EyePoint Pharmaceuticals: the origin and transition 2:29

·       Yutiq and long-acting drug delivery systems 6:07

·       Additional indications for Yutiq 8:30

·       What is the key factor in delivering this longer durability? 16:13

·       Any consideration of looking at superiority of visual acuity and anatomical OCT gains? 21:47

·       Is the primary focus wet AMD? Or are you also looking at NPDR and DME as potential indications? 24:19

·       Investor information and neural protection data 29:01

·       What is the most important issue that the field of ophthalmology is currently facing? 30:38

·       Thanks for listening 32:37

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. You can find Nancy Lurker at @EyePointCEO and @EyePointPharma.

Nancy Lurker is the board director and CEO of EyePoint Pharmaceuticals.

Disclosures: Lurker is the board director and CEO of EyePoint Pharmaceuticals. Mali reports he is founder and CEO of Mali Enterprises; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI.

In this episode, I discuss Samsara Vision’s SING IMT and its benefits of vision improvement for patients with AMD with Rebecca Kammer, OD, PhD.

Brought to you by Alcon

·       Welcome to another exciting episode of Eye Care insider :14

·       Intro for Rebecca Kammer, OD, PhD :27

·       Dr. Kammer’s background 1:28

·       Defining late-stage AMD patients and treatments available 5:11

·       The SING IMT 9:46

·       US Concerto Study Website – to learn more about the study 13:13

·       Visual acuity and the SING IMT 13:48

·       US trial, recruitment and patient eligibility 17:18

·       Contact toll-free 1-866-393-3767 discuss eligibility, participation and questions 20:39

·       SING IMT as an option for patients 22:55

·       Thanks for listening 27:30

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. You can reach Dr. Kammer at rkammer@samsaravision.com.

Rebecca Kammer, OD, PhD, is the vice president of worldwide clinical and medical affairs for Samsara Vision, Inc., an adjunct professor at University of California, Irvine and a diplomate in low vision of the American Academy of Optometry.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI. Kammer reports being a clinical advisor to Biovisics and Eyedaptic.